---
title: "Moleculin reports interim results from MIRACLE trial in r/r AML patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294705884.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-03T10:14:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294705884.md)
  - [en](https://longbridge.com/en/news/294705884.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294705884.md)
---

# Moleculin reports interim results from MIRACLE trial in r/r AML patients

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [Moleculin Biotech Highlights Promising MIRACLE Trial Remission Data](https://longbridge.com/en/news/294515449.md)
- [Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patients](https://longbridge.com/en/news/294510325.md)
- [Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use](https://longbridge.com/en/news/294363759.md)
- [Snap Q2 preview—revenue likely higher as ad recovery remains in focus](https://longbridge.com/en/news/294613965.md)
- [Evommune begins Phase IIb trial of EVO756 for migraine](https://longbridge.com/en/news/294503057.md)